Eli Lilly and Company
Checkpoint inhibitor bispecific antibodies
Last updated:
Abstract:
The present invention relates to antibodies that are heterodimeric and bind human PD-L1 and human PD-1, and may be useful for treating cancer alone and in combination with chemotherapy and other cancer therapeutics.
Status:
Grant
Type:
Utility
Filling date:
9 Jul 2018
Issue date:
21 Dec 2021